2013 (v1)
Publication
No description
Uploaded on: April 14, 2023
-
-
2013 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2014 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2013 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2016 (v1)Publication
There is increasing evidence that natural killer (NK) cells exhibit regulatory features. Among them, CD56bright NK cells have been suggested to play a major role in controlling T cell responses and maintaining homeostasis. Dysfunction in NK cell-mediated regulatory features has been recently described in untreated multiple sclerosis (MS),...
Uploaded on: April 14, 2023 -
2016 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2017 (v1)PublicationIn vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma
Natalizumab (NTZ) is a monoclonal antibody targeting the α4β1 integrin (CD49d/CD29), very late antigen-4 (VLA-4), which is approved for treatment of relapsing-remitting multiple sclerosis (RR-MS). A possible association between NTZ treatment and a higher risk of melanoma is under debate. Natural Killer (NK) cells, which express VLA-4, represent...
Uploaded on: April 14, 2023 -
2016 (v1)Publication
Recent evidence has shown that CD56bright NK cells, a subset of NK cells abundant in lymph nodes, may have an immunoregulatory function. In multiple sclerosis (MS), expansion of CD56bright NK cells has been associated to successful response to different treatments and to remission of disease during pregnancy; how whether they exert...
Uploaded on: March 27, 2023 -
2016 (v1)Publication
No description
Uploaded on: April 14, 2023